Current and Resolved Drug Shortages and Discontinuations Reported to FDA
Report a Drug Shortage |
Contact Us |
FAQ |
Background Info |
Get Email Alerts |
Download Current Drug Shortages
Spectrum Pharmaceuticals
Start Over | Back to Previous Screen
Leucovorin Calcium Lyophilized Powder for Injection
Status: Currently in Shortage
»Date first posted:
No date available
»Therapeutic Categories: Oncology; Pediatric
Spectrum Pharmaceuticals
Fresenius Kabi USA (Revised 03/31/2023)
| Presentation | Availability and Estimated Shortage Duration | Related Information | Shortage Reason (per FDASIA) |
|---|---|---|---|
| 200 mg SDV (NDC 63323-710-50) | Available | Check wholesalers for inventory. | Demand increase for the drug |
| 500 mg SDV (NDC 63323-711-00) | Backordered. Next release April 2023. | Check wholesalers for inventory. | Manufacturing delay |
| 100 mg per 10 mL (10 mg per mL) Single dose amber vial, liquid (NDC 63323-631-10) | Backordered. Next release April 2023. | Check wholesalers for inventory. | Manufacturing Delay |
| 500 mg per 50 mL (10 mg per mL) Single dose amber vial, liquid (NDC 63323-631-50) | Backordered. Next release not available at this time | Check wholesalers for inventory. | Manufacturing Delay |
Hikma Pharmaceuticals USA, Inc. (formerly West-Ward) (Revised 02/09/2023)
| Presentation | Availability and Estimated Shortage Duration | Related Information | Shortage Reason (per FDASIA) |
|---|---|---|---|
| 50 mg, 10 mL vial (NDC 0143-9555-01) | This presentation is temporarily on backorder. | Additional lots are scheduled for manufacturing and will be available in the March 2023 timeframe. Product will be made available as it is released. | Demand increase for the drug |
| 100 mg, 20 mL vial (NDC 0143-9554-01) | Inventory is currently available. | Additional lots are scheduled for manufacturing to meet demand. Product will be made available as it is released. | Demand increase for the drug |
| 200 mg, 30 mL vial (NDC 0143-9553-01) | Inventory is currently available. | Additional lots are scheduled for manufacturing to meet demand. Product will be made available as it is released. | Demand increase for the drug |
| 350 mg, 50 mL vial (NDC 0143-9552-01) | This presentation is temporarily on backorder. | Demand increase for the drug |
Mylan Institutional, a Viatris company (Reverified 03/28/2023)
| Presentation | Availability and Estimated Shortage Duration | Related Information | Shortage Reason (per FDASIA) |
|---|---|---|---|
| 100 mg vial (NDC 67457-528-10) | Re-supply in May 2023 | Demand increase for the drug | |
| 200 mg vial (NDC 67457-529-20) | Re-supply in May 2023 | Demand increase for the drug | |
| 350 mg vial (NDC 67457-530-35) | Re-supply in May 2023 | Demand increase for the drug |
Sagent Pharmaceuticals (Revised 03/22/2023)
| Presentation | Availability and Estimated Shortage Duration | Related Information | Shortage Reason (per FDASIA) |
|---|---|---|---|
| 50 mg vial (NDC 25021-813-10) | Backordered. Estimated availability May 2023 | Over selling forecast | |
| 100mg vial (NDC 25021-814-30) | Allocation. Availability March 2023 | Demand increase | |
| 200mg vial (NDC 25021-815-30) | Backorder. Estimated availability late March/early April 2023 | Over selling forecast | |
| 350mg vial (NDC 25021-816-30) | Available. On allocation. | Demand increase | |
| 500mg vial (NDC 25021-828-50) | Backordered. Availability March 2023 | Manufacturing delay |
Teva Pharmaceuticals (Revised 01/09/2023)
| Presentation | Availability and Estimated Shortage Duration | Related Information | Shortage Reason (per FDASIA) |
|---|---|---|---|
| 100mg/vial, 20mL (NDC 0703-5140-01) | Unavailable | Recovery TBD | Demand increase for the drug |
| 350mg/vial 30mL (NDC 0703-5145-01) | Unavailable | Recovery TBD | Demand increase for the drug |